Advanced liver cancer - Pipeline Insight, 2024

Advanced liver cancer - Pipeline Insight, 2024

DelveInsight’s, “Advanced liver cancer - Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Advanced liver cancer: Understanding

Advanced liver cancer: Overview

Advanced liver cancer, characterized by its progression to later stages, represents a formidable medical challenge due to its propensity for metastasis and the intricate interplay of factors influencing disease progression. At this advanced stage, the cancer has typically infiltrated surrounding tissues and organs, disrupting normal liver function and potentially impacting vital bodily processes. Metastasis, often widespread by this point, can occur in various distant sites beyond the liver, including the lungs, bones, lymph nodes, and other regions, exacerbating the complexity of disease management.

Symptoms associated with advanced liver cancer can be debilitating, significantly impacting the individual's quality of life. These symptoms may manifest in various ways, including abdominal discomfort or pain, unexplained weight loss, jaundice, ascites (abdominal fluid accumulation), and profound fatigue. The presence of such distressing symptoms not only affects the physical well-being of patients but also poses emotional and psychological challenges, necessitating comprehensive support and care strategies tailored to address the multifaceted aspects of the disease experience. Navigating the complexities of advanced liver cancer requires a multidisciplinary approach that extends beyond medical interventions to encompass holistic care focused on symptom management, supportive therapies, and psychosocial support.

Advanced hepatocellular carcinoma (HCC) is a severe malignancy that poses a serious threat to human health. Owing to challenges in early diagnosis, most patients lose the opportunity for radical treatment when diagnosed. Nonetheless, recent advancements in cancer immunotherapy provide new directions for the treatment of HCC. For instance, monoclonal antibodies against immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1/death ligand-1 inhibitors and cytotoxic t-lymphocyte associated antigen-4 significantly improved the prognosis of patients with HCC. However, tumor cells can evade the immune system through various mechanisms. With the rapid development of genetic engineering and molecular biology, various new immunotherapies have been used to treat HCC, including ICIs, chimeric antigen receptor T cells, engineered cytokines, and certain cancer vaccines.

""Advanced liver cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced liver cancer pipeline landscape is provided which includes the disease overview and Advanced liver cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced liver cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced liver cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced liver cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced liver cancer.

Advanced liver cancer Emerging Drugs Chapters

This segment of the Advanced liver cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced liver cancer Emerging Drugs

Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson's mechanism of action is mediated via deregulation of the NF-κB and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

ADI-PEG20: Polaris Pharmaceuticals

Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumors, such as malignant melanoma and hepatocellular carcinoma, are auxotrophic for arginine. These tumors that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline. ADI-PEG20 appears to show inhibitory effects on human melanomas and hepatocellular carcinomas. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

SRF388: Surface Oncology

SRF388 is a fully human IgG1 blocking antibody to IL-27 with potential to promote immune activation in the tumor microenvironment. The immunoregulatory cytokine IL-27 upregulates inhibitory immune checkpoint receptors (eg, PD-L1, TIGIT) and downregulates proinflammatory cytokines (eg, IFNγ, TNFα). Currently, the drug is in the Phase II stage of development to treat Advanced liver cancer.

TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. Currently, the drug is in the Phase I stage of development to treat Advanced liver cancer.

Further product details are provided in the report……..

Advanced liver cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced liver cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced liver cancer

There are approx. 50+ key companies which are developing the therapies for Advanced liver cancer. The companies which have their Advanced liver cancer drug candidates in the most advanced stage, i.e. Phase III include, Can-Fite BioPharma and Polaris Pharmaceuticals.

Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Advanced liver cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced liver cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced liver cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced liver cancer drugs.

Advanced liver cancer Report Insights

Advanced liver cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Advanced liver cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Advanced liver cancer drugs?

How many Advanced liver cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced liver cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced liver cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Advanced liver cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Can-Fite BioPharma

Polaris Pharmaceuticals

SOTIO Biotech

Surface Oncology

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

AstraZeneca

Takeda

Arbele

ImmVira Pharma Co. Ltd

Vaxcell Bio

Eutilex

Biocity Biopharmaceutics Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

OriCell Therapeutics Co., Ltd.

TORL Biotherapeutics, LLC

Shanghai Henlius Biotech

TaiRx, Inc.

Biocity Biopharmaceutics Co., Ltd.

Key Products

Namodenoson

ADI-PEG20

SOT101

SRF388

TQB2223

TAK-500

ARB202

T3011

Vax-NK/HCC

EU307 CAR-T Cell

BC3402

QL1706

Ori-C101

TORL-4-500

HLX07

CVM-1118

BC3402

Please Note: It will take 5-6 business days to complete the report upon order confirmation.